{"title":"Icosapent ethyl for reducing the risk of cardiovascular events","authors":"S. Chaplin","doi":"10.1002/psb.2045","DOIUrl":null,"url":null,"abstract":"Icosapent ethyl (Vazkepa) is an omega‐3 fatty acid prodrug indicated for reducing the risk of cardiovascular events in statin‐treated patients. This article summarises the clinical trial evidence for its efficacy and its place in therapy.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"15 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/psb.2045","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Icosapent ethyl (Vazkepa) is an omega‐3 fatty acid prodrug indicated for reducing the risk of cardiovascular events in statin‐treated patients. This article summarises the clinical trial evidence for its efficacy and its place in therapy.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
